JOIN US

 

Participants

Participants at the Convergence Forum include an invitation-only group of company founders, senior level executives, investors and healthcare leaders along with a select group of service providers who sponsor the program.  Request an invitation or call us at 833-437-1400 if you would like to join us.

Companies joining US at the 2024 Convergence Forum include:

 

AbCellera
Aitia
Aleta Biotherapeutics
Alexandria Real Estate Equities
Alloy Therapeutics
Alnylam Pharmaceuticals
Andreessen Horowitz
Apollo Health Ventures
Aquilo Partners
Arbor Biotechnologies
Armatus
Arrakis Therapeutics
Atlas Venture
Axonis Therapeutics
Baker Tilly
Banc of California
Blackstone Life Sciences
Boston Globe
Brain Tumor Investment Fund
Breakout Ventures
Brigham and Women's Hospital
BrightEdge -
American Cancer Society
Bristol Myers Squibb
Catalyst Pharmaceuticals
CBT Advisors
Cellens
cTap
Ceramedix
CIC
Citizens Private Bank
CLA
ClearCure Biosciences
Commonwealth of MA
Concerto Bio
CRISPR Therapeutics
Current Health
Cytosite Biopharma
DaCapo Brainscience
Damona Pharma
Delix Therapeutics
Delphia Therapeutics
DLA Piper
Editas

Engine Ventures
Entact Bio
Evotec
Eikonizo
Foley & Lardner LLP
Form Bio
Garuda Therapeutics
General Atlantic
GlycoMimetics
Gordian Ventures
GrayBella Capital
Guardian Bio
Halloran Consulting Group
hC Bioscience
Incubate Coalition
Innotech Precision Medicine
Intellia Therapeutics
Ipsen
Isomorphic Labs
Johnson & Johnson Innovation -
JJDC
JRDF T1D Fund
JURA Bio
Karyopharm Therapeutics
Kisbee Therapeutics
Kojin Therapeutics
Kynexis
Larkspur Biosciences
Lassen Therapeutics
Luma Group
Lumira Ventures
Lyndra
MacDougall
MassVentures
Mayo Clinic
Merck
Modulate Bio
Monash University
Morphoceuticals
Myeloma Investment Fund
Myeloid Therapeutics
New York Blood Center Ventures
NextPoint Therapeutics
Nimbus Therapeutics
Normunity

Novartis
Nucleate Bio
Omega Therapeutics
Oncimmune Limited
Orionis Biosciences
Orna Therapeutics
Owkin
Oxford Finance
Paradox Immunotherapeutics
PhagePro
Polaris Partners
Portal Instruments
Psivant Therapeutics
Q32 Bio
RA Capital Management
Rapport Therapeutics
Redesign
RMG Associates
Roivant Social Ventures
ROME Therapeutics
Sanofi
Sante
Satellite Bio
Section 32
Seismic Therapeutic
SiNON Nano Solutions
SLAM BioTherapeutics
Souffle Therapeutics
South Shore Health
SpyBiotech
The Mark Foundation
for Cancer Research
Third Rock Ventures
ThriveLink
Two Bear Capital
UPMC Enterprises
Upstream Bio
Versatope Therapeutics
Vertex Ventures HC
Vigil Neuroscience
Viva Bioinnovator
Walgreens Boots Alliance
WilmerHale
Worldwide Clinical Trials
Wyss Institute